We use cookies for a better user experience. Read our Privacy Policy
I Agree
Liposome Drug Delivery Market
The COVID-19 (coronavirus) has exposed the vulnerabilities of healthcare facilities. Due to the increasing number of COVID-19 patients, especially in the U.S. and European countries, research institutes are pressurized to accelerate their R&D activities to develop drugs and vaccines for the treatment of coronavirus. Thus, companies in the liposome drug delivery market are capitalizing on this opportunity to increase their research in nanomaterials such as nanospheres, liposomes, and nanoparticles that are effective antiviral agents. Liposome drug delivery is being leveraged with increased in vivo and in vitro drug activities for routine clinical practices.
Companies in the liposome drug delivery market are increasing their focus on drug delivery nanosystems involving major antiviral classes and their transport across specific barriers at cellular and intracellular levels. Thus, liposomes hold promising potentials in ongoing research studies being carried out by healthcare companies for the treatment of coronavirus.
To know the scope of our report Get a Sample on Liposome Drug Delivery Market
New strategies in surface modification of liposomes are generating incremental opportunities for pharmaceutical companies. The liposome drug delivery is being highly publicized as a useful biocompatible tool for the vehiculation and delivery of lipophilic, hydrophilic, and ampiphilic compounds. However, high toxicity and resistance in high doses are some of the limitations faced by companies in the liposome drug delivery market. Hence, companies are transitioning from simple conventional vesicles to second-generation liposomes by attuning the lipid composition and surface with different ligands.
Get a glimpse of the in-depth analysis through our Report Brochure
Companies are focusing on surface chemistry of the liposome technology. Increased research in liposome technology are contributing toward a robust CAGR of ~9% for the liposome drug delivery market. PEGylated liposomes are gaining popularity for possessing higher drug loading capacity. Novel drugs such as the CPX-1 encapsulated in liposomes are beneficial for increased disease control in patients suffering from colorectal cancer. As such, the revenue of cancer therapy application segment is projected for aggressive growth during the forecast period.
Liposomes are gaining widespread acceptance as Nano-carriers for diverse pharmaceutical applications. Compositions of phospholipids and cholesterol are becoming increasingly useful in liposome drug delivery. On the other hand, nanotechnology is optimizing liposome drug delivery. Hence, pharmaceutical companies are exploring alternative compositions with cholesterol and new techniques such as nanotechnology to enhance the stability and drug release profiles. They are using liposomes to its full potential for the generation of extracellular vesicles by targeted cells.
Companies in the liposome drug delivery market are increasing their R&D activities to unlock new lipid compositions and strategies that optimize the stability and drug vehiculization capabilities of liposomes. Such experiments are instrumental for innovative liposome fabrication. This explains why the liposome drug delivery market is expected to experience favorable Y-o-Y growth, owing to an estimated revenue of ~US$ 8 Bn by the end of 2027. Thus, innovative designs in liposomal architectures are proving beneficial for improved in vivo and in vitro drug activities.
Therapeutic efficacy of PEGylated liposomal Doxorubicin is being leveraged with improved liposomal formulations of galbanic acid (Gba) in the liposome drug delivery market. Galbanic acid is a sesquiterpene coumarin possessing strong antiangiogenic activity, resulting in promising potential as an anti-cancer agent. However, galbanic acid poses limitations in water solubility, thus hampering its clinical applications. Hence, companies in the market for liposome drug delivery are increasing the applicability of PEGylated liposomal Gba produced through the thin film hydration plus extrusion method to overcome limitations of poor Gba solubility.
Present chemotherapeutic agents in cancer chemotherapy are accompanied with several side effects. Hence, companies in the liposome drug delivery market are increasing their efficacy in PEGylated liposomal Gba to minimize side effects in patients. As such, liposomes are acquiring popularity to enhance circulation time and reduce the systemic toxicity of hydrophobic substances such as Gba to leverage their therapeutic efficacy for drugs in the market of liposome drug delivery.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Liposomes are being highly publicized as potential antiviral agents instrumental in reducing social impact and economic burden caused due to the COVID-19 outbreak. Companies in the liposome drug delivery market are gaining expertise in the formulation of advanced liposomes possessing greater solubility and long circulating time to improve drug release profiles.
Surface chemistry of liposome technology has enabled liposomes to be further liganded with vitamins, carbohydrates, and peptides, among others. However, maintaining physical properties of liposomal formulations poses as a challenge for market players. Hence, companies should refer the NRC’s (National Research Council) certified reference material program to comply with industry standards and maintain physical characteristics of liposomal formulations.
Liposome Drug Delivery Market – Segmentation
|
Product |
Liposomal Doxorubicin Liposomal Paclitaxel Liposomal Amphotericin B Others |
|
Technology |
Stealth Liposome Technology Non-PEGylated Liposome Technology DepoFoam Liposome Technology |
|
Application |
Fungal Diseases Cancer Therapy Pain Management Viral Vaccines Photodynamic Therapy |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Liposome drug delivery market was valued at US$ 3.6 Bn in 2018
Liposome drug delivery market to reach valuation of ~US$ 8 Bn by 2027
Liposome drug delivery market is driven by increase in therapeutic and diagnostic applications
North America accounted for a major share of the global liposome drug delivery market and the trend is expected to continue during the forecast period
Key players in the global liposome drug delivery market include Spectrum Pharmaceuticals, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Acronyms
3. Research Methodology
4. Executive Summary: Global Liposome Drug Delivery Market
5. Market Overview
5.1. Definition
5.2. Market Indicators
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunities
5.4. Global Liposome Drug Delivery Market Revenue (US$ Mn) Forecast 2017–2027
5.5. Global Liposome Drug Delivery Market Outlook
6. Key Insights
6.1. Pipeline Analysis
6.2. Clinically Marketed Liposome Drugs
6.3. Regulatory Scenario Assessment
7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product
7.1. Introduction
7.2. Global Liposome Drug Delivery Market Value Share Analysis, by Product
7.3. Global Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027
7.3.1. Liposomal Doxorubicin
7.3.2. Liposomal Paclitaxel
7.3.3. Liposomal Amphotericin B
7.3.4. Others
7.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Product
8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology
8.1. Introduction
8.2. Global Liposome Drug Delivery Market Value Share Analysis, by Technology
8.3. Global Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
8.3.1. Stealth Liposome Technology
8.3.2. Non-PEGylated Liposome Technology
8.3.3. DepoFoam Liposome Technology
8.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology
9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application
9.1. Introduction
9.2. Global Liposome Drug Delivery Market Value Share Analysis, by Application
9.3. Global Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
9.3.1. Fungal Diseases
9.3.2. Pain Management
9.3.3. Cancer Therapy
9.3.4. Viral Vaccines
9.3.5. Photodynamic Therapy
9.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology
10. Global Liposome Drug Delivery Market Analysis and Forecast, by Region
10.1. Regional Outlook
10.2. Introduction
10.3. Global Liposome Drug Delivery Market Value Forecast, by Region
10.3.1. North America
10.3.2. Europe
10.3.3. Asia Pacific
10.3.4. Latin America
10.3.5. Middle East & Africa
10.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Region
11. North America Liposome Drug Delivery Market Analysis and Forecast
11.1. Key Findings
11.2. North America Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027
11.2.1. Liposomal Doxorubicin
11.2.2. Liposomal Paclitaxel
11.2.3. Liposomal Amphotericin B
11.2.4. Others
11.3. North America Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
11.3.1. Stealth Liposome Technology
11.3.2. Non-PEGylated Liposome Technology
11.3.3. DepoFoam Liposome Technology
11.4. North America Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027
11.4.1. Fungal Diseases
11.4.2. Pain Management
11.4.3. Cancer Therapy
11.4.4. Viral Vaccines
11.4.5. Photodynamic Therapy
11.5. North America Liposome Drug Delivery Market Value Forecast, by Country, 2017–2027
11.5.1. U.S.
11.5.2. Canada
11.6. North America Liposome Drug Delivery Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Technology
11.6.3. By Application
11.6.4. By Country
12. Europe Liposome Drug Delivery Market Analysis and Forecast
12.1. Key Findings
12.2. Europe Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027
12.2.1. Liposomal Doxorubicin
12.2.2. Liposomal Paclitaxel
12.2.3. Liposomal Amphotericin B
12.2.4. Others
12.3. Europe Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
12.3.1. Stealth Liposome Technology
12.3.2. Non-PEGylated Liposome Technology
12.3.3. DepoFoam Liposome Technology
12.4. Europe Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027
12.4.1. Fungal Diseases
12.4.2. Pain Management
12.4.3. Cancer Therapy
12.4.4. Viral Vaccines
12.4.5. Photodynamic Therapy
12.5. Europe Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. U.K.
12.5.2. Germany
12.5.3. France
12.5.4. Italy
12.5.5. Spain
12.5.6. Rest of Europe
12.6. Europe Liposome Drug Delivery Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Technology
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast
13.1. Key Findings
13.2. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027
13.2.1. Liposomal Doxorubicin
13.2.2. Liposomal Paclitaxel
13.2.3. Liposomal Amphotericin B
13.2.4. Others
13.3. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
13.3.1. Stealth Liposome Technology
13.3.2. Non-PEGylated Liposome Technology
13.3.3. DepoFoam Liposome Technology
13.4. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027
13.4.1. Fungal Diseases
13.4.2. Pain Management
13.4.3. Cancer Therapy
13.4.4. Viral Vaccines
13.4.5. Photodynamic Therapy
13.5. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. China
13.5.2. India
13.5.3. Japan
13.5.4. Australia & New Zealand
13.5.5. Rest of Asia Pacific
13.6. Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Technology
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Latin America Liposome Drug Delivery Market Analysis and Forecast
14.1. Key Findings
14.2. Latin America Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027
14.2.1. Liposomal Doxorubicin
14.2.2. Liposomal Paclitaxel
14.2.3. Liposomal Amphotericin B
14.2.4. Others
14.3. Latin America Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
14.3.1. Stealth Liposome Technology
14.3.2. Non-PEGylated Liposome Technology
14.3.3. DepoFoam Liposome Technology
14.4. Latin America Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027
14.4.1. Fungal Diseases
14.4.2. Pain Management
14.4.3. Cancer Therapy
14.4.4. Viral Vaccines
14.4.5. Photodynamic Therapy
14.5. Latin America Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America
14.6. Latin America Liposome Drug Delivery Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Technology
14.6.3. By Application
14.6.4. By Country/Sub-region
15. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast
15.1. Key Findings
15.2. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027
15.2.1. Liposomal Doxorubicin
15.2.2. Liposomal Paclitaxel
15.2.3. Liposomal Amphotericin B
15.2.4. Others
15.3. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027
15.3.1. Stealth Liposome Technology
15.3.2. Non-PEGylated Liposome Technology
15.3.3. DepoFoam Liposome Technology
15.4. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027
15.4.1. Fungal Diseases
15.4.2. Pain Management
15.4.3. Cancer Therapy
15.4.4. Viral Vaccines
15.4.5. Photodynamic Therapy
15.5. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027
15.5.1. GCC Countries
15.5.2. South Africa
15.5.3. Rest of Middle East & Africa
15.6. Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis
15.6.1. By Product
15.6.2. By Technology
15.6.3. By Application
15.6.4. By Country/Sub-region
16. Competition Landscape
16.1. Company Profiles
16.1.1. Spectrum Pharmaceuticals, Inc.
16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.1.2. Financial Overview
16.1.1.3. Product Portfolio
16.1.1.4. Strategic Overview
16.1.1.5. SWOT Analysis
16.1.2. Astellas Pharma Inc.
16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.2.2. Financial Overview
16.1.2.3. Product Portfolio
16.1.2.4. Strategic Overview
16.1.2.5. SWOT Analysis
16.1.3. Gilead Sciences, Inc.
16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.3.2. Financial Overview
16.1.3.3. Product Portfolio
16.1.3.4. Strategic Overview
16.1.3.5. SWOT Analysis
16.1.4. Celsion Corporation
16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.4.2. Financial Overview
16.1.4.3. Product Portfolio
16.1.4.4. Strategic Overview
16.1.4.5. SWOT Analysis
16.1.5. Ipsen Pharma
16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.5.2. Financial Overview
16.1.5.3. Product Portfolio
16.1.5.4. Strategic Overview
16.1.5.5. SWOT Analysis
16.1.6. Pacira BioSciences, Inc.
16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.6.2. Financial Overview
16.1.6.3. Product Portfolio
16.1.6.4. Strategic Overview
16.1.6.5. SWOT Analysis
16.1.7. Luye Pharma Group
16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.7.2. Financial Overview
16.1.7.3. Product Portfolio
16.1.7.4. Strategic Overview
16.1.7.5. SWOT Analysis
16.1.8. Novartis AG
16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.8.2. Financial Overview
16.1.8.3. Product Portfolio
16.1.8.4. Strategic Overview
16.1.8.5. SWOT Analysis
16.1.9. Takeda Pharmaceutical Company Limited
16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.9.2. Financial Overview
16.1.9.3. Product Portfolio
16.1.9.4. Strategic Overview
16.1.9.5. SWOT Analysis
16.1.10. Johnson & Johnson
16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.10.2. Financial Overview
16.1.10.3. Product Portfolio
16.1.10.4. Strategic Overview
16.1.10.5. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis - Liposome Drug Delivery Systems
Table 02: Clinically Marketed Liposome Drugs
Table 03: Regulations - Principle difference between U.S., EU, and India
Table 04: Regulatory Scenario Assessment - Administrative Requirements
Table 05: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 06: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 07: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 08: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 09: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 10: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 11: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 12: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 13: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 15: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 16: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 17: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 19: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 20: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 21: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 23: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 24: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 25: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 26: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 27: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027
Table 28: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027
List of Figures
Figure 01: Global Liposome Drug Delivery Market Snapshot
Figure 02: Global Liposome Drug Delivery Market Value (US$ Mn), by Region, 2018 and 2027
Figure 03: Therapeutic applications of liposomes in drug delivery
Figure 04: Advantages of Liposome Drug Delivery System
Figure 05: Global Liposome Drug Delivery Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2017–2027
Figure 06: Global Liposome Drug Delivery Market Value Share, by Product, 2019
Figure 07: Global Liposome Drug Delivery Market Value Share, by Technology, 2019
Figure 08: Global Liposome Drug Delivery Market Value Share, by Application, 2019
Figure 09: Global Liposome Drug Delivery Market Value Share, by Region, 2019
Figure 10: Regulatory Approval Process - U.S.
Figure 11: Regulatory Approval Process - Europe
Figure 12: Regulatory Approval Process - India
Figure 13: Global Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027
Figure 14: Global Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027
Figure 15: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Doxorubicin, 2017–2027
Figure 16: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Paclitaxel, 2017–2027
Figure 17: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Amphotericin B, 2017–2027
Figure 18: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 19: Global Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027
Figure 20: Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027
Figure 21: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stealth Liposome Technology, 2017–2027
Figure 22: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-PEGylated Liposome Technology, 2017–2027
Figure 23: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DepoFoam Liposome Technology, 2017–2027
Figure 24: Global Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027
Figure 25: Global Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027
Figure 26: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fungal Diseases, 2017–2027
Figure 27: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pain Management, 2017–2027
Figure 28: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Therapy, 2017–2027
Figure 29: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Viral Vaccines, 2017–2027
Figure 30: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Photodynamic Therapy, 2017–2027
Figure 31: Liposome Drug Delivery Market – Regional Outlook
Figure 32: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, 2017–2027
Figure 33: Global Liposome Drug Delivery Market Value Share Analysis, by Region, 2018 and 2027
Figure 34: Global Liposome Drug Delivery Market Attractiveness Analysis, by Region, 2019–2027
Figure 35: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 36: North America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 37: North America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 38: North America Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027
Figure 39: North America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027
Figure 40: North America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027
Figure 41: North America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027
Figure 42: North America Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027
Figure 43: North America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027
Figure 44: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 45: Europe Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 46: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 47: Europe Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027
Figure 48: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027
Figure 49: Europe Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027
Figure 50: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027
Figure 51: Europe Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027
Figure 52: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027
Figure 53: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 54: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 55: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 56: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027
Figure 57: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027
Figure 58: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027
Figure 59: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027
Figure 60: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027
Figure 61: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027
Figure 62: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 63: Latin America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 64: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 65: Latin America Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027
Figure 66: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027
Figure 67: Latin America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027
Figure 68: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027
Figure 69: Latin America Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027
Figure 70: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027
Figure 71: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 72: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 73: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 74: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027
Figure 75: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027
Figure 76: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027
Figure 77: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027
Figure 78: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027
Figure 79: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes